The estimated Net Worth of Nicole La Brosse is at least $1.25 Million dollars as of 22 July 2024. Nicole Brosse owns over 5,000 units of Halozyme Therapeutics stock worth over $978,272 and over the last 3 years Nicole sold HALO stock worth over $269,050.
Nicole has made over 11 trades of the Halozyme Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently Nicole exercised 5,000 units of HALO stock worth $112,500 on 22 July 2024.
The largest trade Nicole's ever made was exercising 30,000 units of Halozyme Therapeutics stock on 26 June 2024 worth over $675,000. On average, Nicole trades about 5,902 units every 74 days since 2022. As of 22 July 2024 Nicole still owns at least 16,472 units of Halozyme Therapeutics stock.
You can see the complete history of Nicole Brosse stock trades at the bottom of the page.
Nicole's mailing address filed with the SEC is C/O HALOZYME THERAPEUTICS, INC., 12390 EL CAMINO REAL, SAN DIEGO, CA, 92130.
Over the last 17 years, insiders at Halozyme Therapeutics have traded over $92,345,799 worth of Halozyme Therapeutics stock and bought 9,720,772 units worth $67,958,365 . The most active insiders traders include Randal J Kirk, David A Ramsay, and Gregory Ian Frost. On average, Halozyme Therapeutics executives and independent directors trade stock every 21 days with the average trade being worth of $3,961,432. The most recent stock trade was executed by Michael J. La Barre on 27 August 2024, trading 5,580 units of HALO stock currently worth $102,728.
we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies
Halozyme Therapeutics executives and other stock owners filed with the SEC include: